Tirtha Chakraborty
Chief Tech/Sci/R&D Officer at VOR BIOPHARMA INC.
Net worth: 429 190 $ as of 30/03/2024
Profile
Tirtha Chakraborty is currently the Chief Scientific Officer at Vor Biopharma, Inc. since 2020 and an Advisor at Specific Biologics, Inc. since 2023.
Previously, Tirtha held the position of Executive Director & Head-Hematology at CRISPR Therapeutics AG from 2015 to 2018 and Vice President-Cell Therapy Research at Sana Biotechnology, Inc. from 2018 to 2019.
Tirtha obtained a doctorate degree from Tata Institute of Fundamental Research.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
VOR BIOPHARMA, INC.
0.27% | 29/02/2024 | 181,093 ( 0.27% ) | 429 190 $ | 30/03/2024 |
Tirtha Chakraborty active positions
| Companies | Position | Start |
|---|---|---|
| VOR BIOPHARMA INC. | Chief Tech/Sci/R&D Officer | 30/09/2019 |
Specific Biologics, Inc.
 Specific Biologics, Inc. Miscellaneous Commercial ServicesCommercial Services Specific Biologics, Inc. is a biotechnology company that focuses on developing gene editing technologies to treat diseases through precision gene editing. The company is based in Toronto, Canada. The Canadian company's two-site dualase™ platform gene editors cut DNA in a way that optimally exploits the cells naturally occurring DNA repair pathways, enabling two gene editing outcomes, precise DNA deletions to disrupt genes or increased repair to correct genes. Specific also develops lipid nanoparticles to deliver the gene editor to target cells and is developing a pipeline of dualase™-based therapeutics in areas of high unmet medical need. The company was founded in 2017. The CEO is Brent Stead. | Consultant / Advisor | 23/07/2023 |
Former positions of Tirtha Chakraborty
| Companies | Position | End |
|---|---|---|
| SANA BIOTECHNOLOGY, INC. | Corporate Officer/Principal | 30/09/2019 |
| CRISPR THERAPEUTICS AG | Director/Board Member | 30/09/2018 |
Training of Tirtha Chakraborty
| Tata Institute of Fundamental Research | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| CRISPR THERAPEUTICS AG | Health Technology |
| VOR BIOPHARMA INC. | Health Technology |
| SANA BIOTECHNOLOGY, INC. | Health Technology |
| Private companies | 1 |
|---|---|
Specific Biologics, Inc.
Specific Biologics, Inc. Miscellaneous Commercial ServicesCommercial Services Specific Biologics, Inc. is a biotechnology company that focuses on developing gene editing technologies to treat diseases through precision gene editing. The company is based in Toronto, Canada. The Canadian company's two-site dualase™ platform gene editors cut DNA in a way that optimally exploits the cells naturally occurring DNA repair pathways, enabling two gene editing outcomes, precise DNA deletions to disrupt genes or increased repair to correct genes. Specific also develops lipid nanoparticles to deliver the gene editor to target cells and is developing a pipeline of dualase™-based therapeutics in areas of high unmet medical need. The company was founded in 2017. The CEO is Brent Stead. | Commercial Services |
- Stock Market
- Insiders
- Tirtha Chakraborty
